[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ruijin Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":599},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,300,0,25,[9,42,69,91,113,134,154,173,200,226,250,272,291,318,340,365,389,415,438,464,484,512,536,556,574],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100652808","effects-of-goat-milk-formula-on-gastrointestinal-comfort-and-growth-in-infants-100652808",false,"NCT07778927","Effects of Goat Milk Formula on Gastrointestinal Comfort and Growth in Infants","A Multicenter, Randomized, Controlled Trial to Evaluate the Effects of Goat Milk Formula on Gastrointestinal Comfort, Behavioral Status, and Early Growth and Development in Infants","Inclusion Criteria:\n\n* Infants aged 0 to 5 months at enrollment\n* Full-term birth (gestational age ≥37 weeks)\n* Birth weight ≥2500 g\n* Infants with symptoms of gastrointestinal discomfort (e.g., abdominal distension, excessive crying, regurgitation, or feeding intolerance)\n* Parents or legal guardians able and willing to provide written informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Infants with known or suspected organic gastrointestinal diseases (e.g., congenital malformations, Hirschsprung disease)\n* History of severe perinatal complications or significant systemic diseases\n* Known or suspected cow's milk protein allergy or other food allergies\n* Use of antibiotics, probiotics, or other medications that may affect gastrointestinal function within 2 weeks prior to enrollment\n* Participation in another clinical study within the past 3 months\n* Any condition that, in the investigator's judgment, may interfere with study participation or outcome assessment For the reference cohort: healthy breastfed infants without significant gastrointestinal symptoms",true,"ALL","5 Months",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","Infant gastrointestinal discomfort is common in early life and can affect feeding, sleep, and overall well-being. Goat milk formula, due to its unique protein composition and smaller fat globules, may be easier to digest and potentially improve gastrointestinal tolerance in infants.\n\nThis study is a multicenter, randomized, controlled trial designed to evaluate the effects of goat milk formula compared with standard cow milk formula in infants aged 0-5 months with gastrointestinal discomfort. The study will assess improvements in gastrointestinal symptoms, overall comfort, behavioral status, and early growth and development, as well as explore potential changes in gut microbiota and intestinal inflammation.",[28,29],"Functional Gastrointestinal Disorders (FGIDs)","Infant Discomfort","NOT_YET_RECRUITING","2026-08-20",{"date":33,"type":34},"2026-08-21","ACTUAL",{"date":36,"type":22},"2026-08-01",{"date":38,"type":22},"2027-12-31",{"name":40,"class":41},"Ruijin Hospital","OTHER",{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":18,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100652408","stn-ttis-with-different-intervention-intervals-versus-standard-medical-treatment-for-parkinsons-disease-100652408","NCT07774312","STN-tTIS With Different Intervention Intervals Versus Standard Medical Treatment for Parkinson's Disease","STN-targeted Temporal Interference Stimulation With Different Intervention Intervals Versus Standard Medical Treatment for Parkinson's Disease: A Multicenter, Randomized, Controlled Trial","Inclusion Criteria:\n\n* 1.Aged 50-85 years, male or female.\n* 2.Diagnosed with idiopathic Parkinson disease (PD) in accordance with the Chinese Guidelines for the Diagnosis and Treatment of Parkinson's Disease (4th Edition), with a confirmed diagnosis for at least 6 months and a stable condition, defined as no significant deterioration or major medication adjustment within the past month.\n* 3.Receiving stable doses of antiparkinsonian medication (e.g., levodopa or dopamine agonists) and willing to maintain the medication regimen during the study.\n* 4.Hoehn and Yahr stage 1-3 in the medication ON state.\n* 5.Baseline MDS-UPDRS Part III total score ≥20 in the medication ON state.\n* 6.No history of non-invasive neuromodulation therapy, or discontinuation of such therapy for at least 3 months before enrollment if previously received.\n* 7.Normal cognitive function (MoCA score ≥24) and able to cooperate with tTIS intervention, clinical scale assessments, and basic smartphone- and smartwatch-assisted home-based motor self-assessments.\n* 8.Able and willing to provide written informed consent and complete all required study procedures and follow-up assessments.\n\nExclusion Criteria:\n\n* 1.Other neurological disorders that may affect motor or cognitive function.\n* 2.Contraindications to magnetic resonance imaging (MRI), such as claustrophobia.\n* 3.History of taking antipsychotics, antidepressants, or other medications affecting dopamine levels.\n* 4.Psychiatric disorders (e.g., depression or schizophrenia), substance abuse, or alcohol dependence.\n* 5.Implanted medical devices (e.g., pacemaker or defibrillator), metal implants in the cranium or spine, a personal or family history of epilepsy, or severe skull defects.\n* 6.Previous deep brain stimulation (DBS) or other intracranial implantation surgery, or participation in another Parkinson disease clinical trial within the past 3 months.","50 Years","85 Years",{"count":52,"type":22},60,[25],"The goal of this clinical trial is to compare the efficacy and safety of different Intervention Intervals of subthalamic nucleus-targeted transcranial temporal interference stimulation (STN-tTIS) in patients with Parkinson disease.\n\nPrevious studies suggest that STN-tTIS may improve motor symptoms in people with Parkinson disease. However, most previous studies evaluated only one stimulation session. It remains unclear how often STN-tTIS should be administered during a repeated treatment course and whether shorter intervention intervals stimulation produces greater or longer-lasting improvement without increasing adverse events.\n\nThe main questions this study aims to answer are:\n\n1. Does STN-tTIS administered five times weekly improve motor symptoms more than standard medication treatment alone at the end of the 2-week treatment period?\n2. Do once-weekly, twice-weekly, and five-times-weekly STN-tTIS produce different changes in motor symptoms?\n3. Does the STN-tTIS intervention intervals influence how long its effects persist after treatment?\n4. Do the different intervention intervals have different effects on non-motor symptoms, quality of life, cognitive function, and safety?\n\nParticipants will be randomly assigned to receive STN-tTIS once weekly, twice weekly, or five times weekly for 2 weeks, or to continue standard antiparkinsonian medication without additional stimulation. All participants will maintain a stable medication regimen during the study. Their motor and non-motor symptoms will be assessed during the treatment period and during a subsequent 2-week follow-up period.",[56],"Parkinson's Disease (PD)",[58,59,60],"Subthalamic nucleus","Transcranial Temporal Interference Stimulation","Intervention Intervals","RECRUITING",{"date":33,"type":34},{"date":64,"type":34},"2026-07-27",{"date":66,"type":22},"2027-04-15",{"name":40,"class":41},1,{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":68},"100652623","clinical-applications-of-fapi-pet-in-solid-tumors-100652623","NCT07776899","Clinical Applications of FAPI PET in Solid Tumors","Clinical Applications of Novel FAPI PET in Diverse Solid Tumors","Inclusion Criteria:\n\n1. Age ≥ 18 years and ≤ 80 years, regardless of gender.\n2. Participants with suspected, confirmed, or suspected recurrent solid tumors.\n3. Participants who agree to participate in this clinical trial and provide written informed consent.\n4. Participants with good compliance, who commit to adhering to the study procedures and cooperate with the full study process.\n5. No plans for pregnancy within 6 months.\n\nExclusion Criteria:\n\n1. Patients with severe medical conditions that, in the investigator's opinion, make them unsuitable for participation in this clinical study, including but not limited to: severe cardiopulmonary insufficiency, severe bone marrow suppression, and severe hepatic or renal insufficiency.\n2. Patients with claustrophobia, severe psychiatric symptoms, or impaired consciousness that precludes cooperation with the examination procedures.\n3. Patients who have received any anti-tumor therapy during the interval between the two PET imaging sessions.\n4. Pregnant or breastfeeding women.\n5. Patients with poor compliance.","18 Years","80 Years",{"count":79,"type":22},200,[25],"The study systematically evaluates the diagnostic performance of FAPI-RuiJ and FAPI-04 PET\u002FCT or PET\u002FMR in various solid tumor types, and is expected to provide a novel molecular imaging tool for early lesion detection, accurate staging, and recurrence surveillance in patients with solid tumors.",[83],"Solid Tumor","2026-08-17",{"date":31,"type":34},{"date":87,"type":34},"2026-07-02",{"date":89,"type":22},"2029-03-31",{"name":40,"class":41},{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":18,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":68},"100652528","phase-1-a-prospective-exploratory-study-of-the-safety-and-preliminary-efficacy-of-the--syn-h21-monoclonal-antibody-in-patients-with-multiple-system-atrophy-100652528","NCT07774585","A Prospective Exploratory Study of the Safety and Preliminary Efficacy of the α-Syn H21 Monoclonal Antibody in Patients With Multiple System Atrophy","Inclusion Criteria:\n\n* Age 45 to 75 years, male or female\n* Diagnosis of Multiple System Atrophy meeting current clinical diagnostic criteria for probable or possible MSA\n* Disease duration of 2 years or less from onset of motor or autonomic symptoms\n* Clinically stable disease without significant fluctuation or acute worsening within 4 weeks before enrollment\n* Able to comply with study procedures and follow-up assessments\n* Mini-Mental State Examination (MMSE) score not consistent with significant dementia\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* History or presence of other neurological disorders that may interfere with study assessments, including Parkinson's disease, progressive supranuclear palsy, corticobasal degeneration, or stroke\n* Severe cognitive impairment or psychiatric disorder, including clinically significant depression or anxiety\n* Severe cardiac, hepatic, renal, or other major systemic disease\n* History of severe hypersensitivity to monoclonal antibody therapies Pregnant or breastfeeding women\n* Women or men unwilling to use effective contraception during the study\n* Participation in another clinical trial or receipt of investigational treatment within 3 months before enrollment\n* Any other condition that, in the investigator's judgment, would make participation inappropriate","45 Years","75 Years",{"count":100,"type":22},3,[102],"PHASE1","Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by autonomic dysfunction, parkinsonism, and cerebellar ataxia. Abnormal aggregation of alpha-synuclein is believed to play an important role in disease progression. The α-Syn H21 monoclonal antibody is designed to selectively bind pathological alpha-synuclein aggregates and may reduce their spread and related neuroinflammation.\n\nThis single-center, prospective, exploratory study will evaluate the safety, tolerability, and preliminary efficacy of the α-Syn H21 monoclonal antibody in patients with MSA. Participants will receive intravenous infusions of H21 every 4 weeks for 3 doses and will be followed for 12 weeks. Clinical symptoms, laboratory tests, imaging findings, and adverse events will be assessed to determine whether H21 may provide clinical benefit and support future larger studies.",[105],"Multiple System Atrophy",{"date":107,"type":34},"2026-08-19",{"date":109,"type":22},"2026-09-15",{"date":111,"type":22},"2026-12-31",{"name":40,"class":41},{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":123,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":4},"100652496","phase-2-pirtobrutinib-combined-with-beam-for-asct-in-relapsed-and-refractory-dlbcl-100652496","NCT07774299","Pirtobrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL","A Multicenter, Single-Arm Clinical Study of Pirtobrutinib Combined With Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preconditioning Regimen for ASCT in Relapsed and Refractory DLBCL","Inclusion Criteria:\n\n1. According to world Health Organization (WHO) classification of disease, diffuse large B-cell lymphoma was confirmed by histology, CR or PR after second-line and above treatment;\n2. 18≤ age ≤70 years old, male or female;\n3. ECOG score 0-2;\n4. No serious organic lesions in the main organs, meeting the requirements of the following laboratory examination indicators (conducted within 7 days before treatment) :\n\n   1. White blood cell count ≥3.0×109\u002FL, absolute neutrophil count ≥1.5×109\u002FL, Hemoglobin ≥90g\u002FL, platelet ≥75×109\u002FL;\n   2. Total bilirubin ≤1.5× upper normal value (ULN);\n   3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5× ULN; Bilirubin ≤1.5× ULN\n   4. Creatinine clearance was 44-133 mmol\u002FL;\n5. No cardiac dysfunction;\n6. Life expectancy over 3 months;\n7. The subject or his\u002Fher legal representative must provide written informed consent prior to conducting a special study examination or procedure.\n\nExclusion Criteria:\n\n1. Previously received autologous hematopoietic stem cell transplantation;\n2. Suffering from serious complications or severe infection;\n3. Central nervous system lymphoma was excluded;\n4. A history of other malignant tumors within 5 years, excluding early tumors treated for curative purposes;\n5. Patients with uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases, etc.;\n6. HBsAg, HCV or HIV positive. Positive HBV and HCV serology is allowed, but DNA\u002FRNA testing must be negative;\n7. Left ventricular ejection fraction ≦ 50%;\n8. Laboratory test value during screening;\n\n   ① Neutrophils \\\u003C1.5×109\u002FL; Platelet \\\u003C75×109\u002FL;\n\n   ② Bilirubin was 1.5 times higher than the normal upper limit, transaminase was 2.5 times higher than the normal upper limit;\n\n   ③ The creatinine level is higher than 1.5 times the upper limit of normal value;\n9. Other concurrent and uncontrolled medical conditions considered by the investigator would affect the patient's participation in the study;\n10. Psychiatric patients or other patients known or suspected to be unable to fully comply with the study protocol;\n11. Pregnant or lactating women;\n12. The researcher judged that the patients were not suitable for this study.","70 Years",{"count":122,"type":22},28,[124],"PHASE2","This trial is a prospective, multi-center, single-arm clinical research. The intention is to evaluate the efficacy and safety of pirtobrutinib combined with BEAM as a pretreatment regimen for ASCT in relapsed and refractory DLBCL patients.",[127],"DLBCL",{"date":107,"type":34},{"date":130,"type":22},"2026-08-25",{"date":132,"type":22},"2029-08-25",{"name":40,"class":41},{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},"100652485","phase-1-exploration-of-circular-rna-in-b-cell-hematologic-malignancies-100652485","NCT07774572","Exploration of Circular RNA in B-cell Hematologic Malignancies","A Phase 1, Open-Label, Single-Arm, Dose-Escalation, Investigator-Initiated Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of an In Vivo Circular RNA Chimeric Antigen Receptor (CAR) T Cell Therapy in Adult Participants With Relapsed or Refractory B-Cell Malignancies","Inclusion Criteria:\n\n1. Age ≥ 18 years, any gender.\n2. Able to provide written informed consent.\n3. Confirmed diagnosis of relapsed\u002Frefractory (R\u002FR) CD19-positive B-cell malignancy, including:\n\n   * Diffuse large B-cell lymphoma (DLBCL)\n   * Follicular lymphoma (FL)\n   * Mantle cell lymphoma (MCL)\n   * Small lymphocytic lymphoma (SLL)\u002Fchronic lymphocytic leukemia (CLL)\n   * Waldenström macroglobulinemia (WM)\n   * Marginal zone lymphoma (MZL)\n4. ECOG performance status 0 or 1.and have archival tumor biopsy tissue and pathology report from the most recent relapse, or at least one palpable superficial tumor lesion at screening, and agree to biopsy\u002Fresection before the first dose of IP for disease confirmation.\n5. Disease refractory to or relapsed after ≥ 2 prior lines of standard therapy, including required agents per disease subtype (e.g., anti-CD20, BTK inhibitors, chemotherapy, or ASCT if applicable).\n6. Measurable disease per Lugano 2014 or iwCLL 2018 criteria.\n7. LVEF ≥ 40% by echocardiogram.\n8. For patients with prior CD19-targeted therapy, confirmed CD19 positivity at screening.\n9. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test and agree to use effective contraception during the study and for 6 months after last treatment.\n10. Male patients with female partners must agree to use condoms, and partners must use effective contraception, during the study and for 6 months after last treatment.\n\nExclusion Criteria:\n\n1. Prior anticancer therapy-related toxicities unresolved to baseline or ≤ Grade 1 (alopecia and peripheral neuropathy excepted).\n2. Central nervous system (CNS) involvement by lymphoma.\n3. Need for urgent treatment due to tumor mass effect or spinal cord compression.\n4. Known hypersensitivity to any component of IP, including mRNA\u002FLNP-based products.\n5. History of another primary malignancy within the past 3 years, except adequately treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ.\n6. Active hepatitis B (HBsAg-positive with detectable HBV DNA) or hepatitis C (HCV RNA-positive) infection.\n7. Active or prior HIV infection.\n8. Uncontrolled active systemic infection requiring IV therapy within 1 week before dosing.\n9. Active or history of acute\u002Fchronic GVHD.\n10. Inadequate hematologic function (ANC \\\u003C1.0×10⁹\u002FL, Hb \\\u003C70 g\u002FL, PLT \\\u003C50×10⁹\u002FL, lymphocytes ≤0.5×10⁹\u002FL) or coagulation abnormalities (INR\u002FAPTT ≥1.5×ULN).\n11. Hepatic impairment (ALT\u002FAST \\>2×ULN, or \\>3×ULN with hepatic involvement; bilirubin \\>2×ULN, unless Gilbert syndrome).\n12. Renal impairment (CrCl \\\u003C50 mL\u002Fmin by Cockcroft-Gault).\n13. Uncontrolled ischemic heart disease, NYHA Class III-IV heart failure, or baseline QTcF ≥450 ms (male) \u002F ≥470 ms (female).\n14. Severe psychiatric disorder history.\n15. Pregnancy or breastfeeding.\n16. Received prohibited treatments within 4 weeks before dosing, including high-dose corticosteroids (\\>20 mg prednisone equivalent daily), chemotherapy, immunosuppressive therapy, prior CAR-T or other gene\u002Fcell therapy, or T-cell engagers.\n17. Participation in another clinical study with investigational therapy within 3 months before dosing, or prior participation in cell\u002Fgene therapy trials.\n18. Planned radiotherapy within 6 weeks after screening (unless only non-irradiated PET-positive lesions remain eligible).\n19. Planned allogeneic HSCT within 90 days after screening.\n20. Significant comorbidities or unstable medical conditions deemed by the investigator to compromise safety or study compliance.",{"count":142,"type":22},30,[102],"This is an investigator-initiated, open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics (PD), and preliminary efficacy of an in vivo circular RNA chimeric antigen receptor T cell in adult participants with R\u002FR B-cell malignancies.",[146],"Lymphoma, B-Cell Refractory",{"date":107,"type":34},{"date":149,"type":34},"2026-05-26",{"date":151,"type":22},"2029-03",{"name":40,"class":41},2,{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":98,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":163,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":68},"100652435","non-invasive-neuromodulation-for-essential-tremor-long-term-safety-and-effectiveness-study-100652435","NCT07774598","Non-Invasive Neuromodulation for Essential Tremor: Long-Term Safety and Effectiveness Study","A Prospective, Single-Center, Single-Arm, Open-Label Clinical Study Evaluating the Long-Term Safety and Efficacy of Transcutaneous Afferent Patterned Stimulation (TAPS) in Patients With Essential Tremor","Inclusion Criteria:\n\n* Adults aged ≥18 and \\\u003C75 years\n* Clinical diagnosis of essential tremor (ET), characterized by postural and\u002For kinetic tremor, primarily affecting one or both upper limbs, with or without involvement of other body regions (e.g., head, voice, or lower limbs)\n* At least one major hand task score ≥2 on the TETRAS (The Essential Tremor Rating Assessment Scale), and a score ≥3 on the Bain \\& Findley Activities of Daily Living (BF-ADL) scale\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Presence of implanted electronic medical devices (e.g., deep brain stimulator or cardiac pacemaker)\n* History of thalamotomy or other neurosurgical procedures for tremor\n* History of epilepsy\n* Current treatment with botulinum toxin for upper limb tremor\n* Skin lesions on the upper limb at the stimulation site (e.g., tumors, hemangiomas)\n* Neurological disorders affecting the upper limbs\n* Known allergy to device materials (e.g., silicone, cotton textiles)\n* Pregnant women\n* Intake of caffeine or excessive alcohol within 8 hours prior to enrollment\n* Severe cardiovascular or cerebrovascular diseases, or other significant neurological disorders\n* Inability to comply with study procedures or follow-up",{"count":162,"type":22},50,[25],"This is a prospective, single-center, single-arm, open-label clinical study designed to evaluate the long-term efficacy and safety of non-invasive neuromodulation using transcutaneous afferent patterned stimulation (TAPS) in patients with essential tremor (ET).\n\nEssential tremor is a common movement disorder that can significantly impair daily functioning and quality of life. Pharmacological treatments are often limited by suboptimal efficacy or adverse effects, highlighting the need for alternative therapeutic approaches.\n\nIn this study, eligible participants with essential tremor will receive TAPS treatment over a defined follow-up period. Clinical outcomes, including tremor severity, functional performance, and patient-reported outcomes, will be assessed longitudinally to evaluate treatment effectiveness. Safety will be monitored throughout the study by recording adverse events and device-related complications.\n\nThe results of this study aim to provide clinical evidence regarding the long-term therapeutic potential and safety profile of TAPS as a non-invasive neuromodulation strategy for essential tremor.",[166],"Essential Tremor",{"date":107,"type":34},{"date":169,"type":34},"2025-12-15",{"date":171,"type":22},"2027-06-15",{"name":40,"class":41},{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":183,"briefSummary":184,"conditions":185,"keywords":190,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":197,"leadSponsor":199,"locationsCount":68},"100652055","ccta-based-vs-cag-based-cabg-a-multicenter-pragmatic-non-inferiority-trial-100652055","NCT07769008","CCTA-Based vs CAG-Based CABG: A Multicenter Pragmatic Non-Inferiority Trial","Coronary Computed Tomography Angiography-Based Versus Coronary Angiography-Based Coronary Artery Bypass Grafting: A Multicenter Pragmatic Non-Inferiority Randomized Controlled Trial","CtaCAB","Inclusion Criteria:\n\n* Referred to CABG treatment\n\nExclusion Criteria:\n\n* Under the age of 18 years\n* Unable to provide informed consent\n* Emergency CABG\n* Redo-CABG\n* Prior PCI with coronary stent implantation\n* Cardiogenic shock\n* Unable to undergo CAG or CCTA examination or deemed unsuitable by the investigator, such as:\n\nKnown allergy to iodinated contrast media; Active hyperthyroidism or uncontrolled thyroid disease; Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m²; Atrial fibrillation with rapid ventricular response or severe arrhythmias not amenable to rate control;\n\n* Pregnancy, lactation, or childbearing potential without effective contraception in female participants\n* Concurrent participation in another interventional trial",{"count":182,"type":22},826,[25],"The goal of this clinical trial is to find out if using a non-invasive heart scan (called coronary computed tomography angiography, or CCTA) to plan coronary artery bypass grafting (CABG) works as well as the standard invasive approach (called coronary angiography, or CAG) for people with blocked heart arteries.\n\nThe main questions it aims to answer are:\n\nDo people who have surgery planned with the non-invasive heart scan have similar health outcomes at 1 year as those who have surgery planned with the standard invasive approach? How does the non-invasive approach compare in terms of heart attacks, strokes, unplanned repeat procedures, and longer hospital stays? Researchers will compare two groups of participants. One group will have their surgery planned using only the CCTA . The other group will have their surgery planned using only the CAG. Both groups will undergo the CABG per local protocol.\n\nParticipants will:\n\nBe randomly assigned (like flipping a coin) to one of the two planning approaches Undergo CABG as scheduled Return for follow-up visits at sugery days, 7 days, 1 month, 6 months, and 1 year after surgery Have a follow-up CCTA scan at 7 days and 1 year to check if the new bypass grafts are working well",[186,187,188,189],"Coronary Artery Disease","Coronary Artery Bypass Grafting","Coronary Computed Tomography Angiography","Coronary Angiography (CAG)",[191,192,193,194],"Major Adverse Cardiovascular Events (MACE)","Coronary Artery Bypass Grafting (CABG)","Coronary Computed Tomography Angiography(CCTA)","Coronary Angiography(CAG)",{"date":107,"type":34},{"date":84,"type":34},{"date":198,"type":22},"2029-08",{"name":40,"class":41},{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":18,"minAge":207,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":212,"conditions":213,"keywords":216,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":4},"100627505","partially-hydrolyzed-whey-protein-formula-for-infants-with-mild-allergy-100627505","NCT07449507","Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy","A Multicenter, Randomized Controlled Study of a Partially Hydrolyzed Whey Protein Formula in Infants With Mild Allergy.","Inclusion Criteria:\n\n1. Infants aged ≥12 weeks and \\\u003C20 weeks at the time of screening.\n2. Gestational age ≥37 weeks.\n3. Birth weight ≥2500g.\n4. Presence of mild allergic symptoms (e.g., skin, gastrointestinal, or respiratory symptoms).\n5. Infants who are predominantly formula-fed or mixed-fed at the time of enrollment.\n6. Legal guardian has provided written informed consent and agrees to participate in the study.\n\nExclusion Criteria:\n\n1. Diagnosed with moderate or severe food allergies, including a history of allergic conditions such as atopic dermatitis, wheezing bronchitis, or severe allergic reactions.\n2. Confirmed cow's milk protein allergy.\n3. Currently receiving a partially hydrolyzed formula or any other specialized formula.\n4. Exclusively breastfed infants.\n5. Known allergy or intolerance to the study formula.\n6. Presence of severe illness (e.g., digestive, respiratory, neurological infections, other gastrointestinal diseases, gastrointestinal anatomical abnormalities, congenital malformations, or growth retardation).\n7. Infants with a history of severe diseases such as heart, brain, liver, kidney, hematologic, connective tissue, endocrine diseases, or mental disorders.\n8. Infants who have undergone major surgery that may impact the study outcomes.\n9. Infants who have used systemic immune-modulating medications (e.g., anti-allergy drugs, corticosteroids, immunosuppressants, biological agents) within the last 2 weeks.\n10. Infants who have used gastrointestinal medications (e.g., proton pump inhibitors, gastrointestinal motility agents, or digestive remedies) within the last 7 days.\n11. Infants who have used probiotics within the last 7 days.\n12. Parents who are unable to report the occurrence of symptoms or adhere to the study visits and protocol requirements.","12 Weeks","20 Weeks",{"count":210,"type":22},160,[25],"This study is a prospective, multicenter, randomized controlled trial designed to evaluate the clinical efficacy, tolerance, and safety of a partially hydrolyzed whey protein formula in infants with mild allergic symptoms. Partially hydrolyzed formulas contain low-molecular weight peptides and have been shown to improve protein tolerance and digestibility and to reduce allergenicity compared with intact cow's milk protein formulas. However, evidence regarding their therapeutic effects in infants who have already developed allergic symptoms remains limited.\n\nEligible infants with mild allergic manifestations who are predominantly formula-fed will be randomly assigned in a 1:1 ratio to receive either a partially hydrolyzed whey protein formula or an intact cow's milk protein formula. Infants in the intervention group will receive a 100% partially hydrolyzed whey protein formula during the initial intervention period and will transition to a 60% partially hydrolyzed whey protein formula after reaching 6 months of age, while infants in the control group will continue feeding with an intact protein formula.\n\nThe primary outcome is the overall improvement rate of allergic symptoms after 2 weeks of intervention. Secondary outcomes include tolerance after transition to the follow-on formula at 6 months of age, changes in skin, gastrointestinal, and respiratory symptoms, growth parameters, and safety outcomes. The results of this study are expected to provide evidence to support nutritional management strategies for infants with mild allergic symptoms.",[214,215],"Mild Allergic Symptoms in Infants","Infant Feeding Intolerance",[217,218],"Allergy","infant",{"date":220,"type":34},"2026-08-18",{"date":222,"type":22},"2027-01-01",{"date":224,"type":22},"2028-12-31",{"name":40,"class":41},{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":18,"minAge":233,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":23,"phases":237,"briefSummary":238,"conditions":239,"keywords":241,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":249,"locationsCount":4},"100608243","dietary-restriction-efficiency-assessment-in-cmpa-100608243","NCT07199023","Dietary Restriction Efficiency Assessment in CMPA","Dietary Restriction Efficiency Assessment of Different Hypoallergenic Formulas in Patients With Suspected Cow's Milk Protein Allergy","Inclusion Criteria:\n\n* Infants aged 0-6 months;\n* Diagnosed with suspected CMPA at the time of presentation;\n* Artificially or mixed-feeding;\n* Parents willing to sign a written informed consent and comply with the study - protocol.\n\nExclusion Criteria:\n\n* Infants currently receiving eHF or AAF formula;\n* Mixed-feeding infants whose current daily formula intake is less than 50% of their total milk intake or less than 200 ml;\n* Infants who have already started adding complementary foods;\n* Infants who have experienced severe food allergy symptoms such as shock, severe vomiting, etc. after taking cow's milk protein;\n* Infants with clinical manifestations of systemic allergic reaction or respiratory difficulties such as acute laryngeal edema or bronchial obstruction;\n* Infants who have used prednisolone or anti-allergic drugs in the past 2 weeks;\n* Infants with contraindications to eHF or AAF formula;\n* Infants whose parents are unable to fully report the occurrence of possible symptoms (e.g., insufficient language skills);\n* Infants with other serious diseases, including but not limited to growth retardation, metabolic disorders, kidney disease, congenital heart disease, medical conditions requiring hospitalization for more than 2 weeks, etc.;\n* Infants whose mothers are unable to avoid necessary foods when mixed-feeding.","0 Months","6 Months",{"count":236,"type":22},360,[25],"This clinical trial aims to evaluate and compare the efficacy of amino acid formula (AAF) and extensively hydrolyzed formula (eHF) in relieving symptoms in infants suspected of cow's milk protein allergy (CMPA) during the diagnostic elimination diet phase. The study will also assess treatment compliance, economic costs, and develop a CMPA screening score suitable for Chinese infants.\n\nEligible infants (0-6 months old) will be randomized to receive either AAF or eHF for at least 2 weeks. Symptom improvement will be evaluated, followed by an oral food challenge (OFC) to confirm CMPA diagnosis. Infants in the eHF group who do not improve may switch to AAF for further evaluation. The total duration of participation is approximately 6 to 8 weeks.\n\nThe study aims to provide evidence-based data to optimize diagnostic pathways and improve quality of life for infants with CMPA.",[240],"Cow's Milk Protein Allergy",[242,243,244],"Amino Acid Formula","Extended Hydrolyzed Formula","Cow's milk protein allergy",{"date":220,"type":34},{"date":247,"type":22},"2026-09-01",{"date":224,"type":22},{"name":40,"class":41},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":98,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":68},"100594933","phase-1-ibi343-combined-with-sintilimab-plus-chemotherapy-in-gastric-cancer-100594933","NCT07025889","IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer","IBI343 Combined With Sintilimab Plus Chemotherapy in Previously Untreated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Dragon15)","Inclusion Criteria:\n\n* 1\\. Able and willing to sign a written Informed Consent Form (ICF) and to comply with protocol-specified visits and related procedures.\n\n  2\\. Age was 18-75 years at the time of signing the ICF, and gender was unlimited.\n\n  3\\. Has histopathologically confirmed unresectable locally advanced or metastatic adenocarcinoma of the gastric\u002Fgastroesophageal junction (G\u002FGEJ AC).\n\n  4\\. No received systemic therapy. 5. Has histopathologically confirmed CLDN18.2-positive disease. 6. Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.\n\nExclusion Criteria:\n\n* 1\\. Has HER2-positive (defined as immunohistochemistry \\[IHC\\] 3+, or IHC 2+ and positive by in situ hybridization) disease.\n\n  2\\. Is currently participating in another interventional clinical study, except when the subject is during survival follow-up of an interventional clinical study.\n\n  3\\. Has a history of treatment with topoisomerase inhibitor-based antibody-drug conjugate(s).",{"count":258,"type":22},55,[102,124],"This is a Single-arm, Open-label, Phase 1b\u002F2 Study of IBI343 Combined with Sintilimab Plus Chemotherapy in Previously Untreated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma",[262],"Gastric Cancer",[262,264,265],"IBI 343","Sintilimab",{"date":220,"type":34},{"date":268,"type":34},"2025-06-02",{"date":270,"type":22},"2028-06",{"name":40,"class":41},{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":281,"phases":4,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":285,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":68},"100526651","risk-factors-and-outcomes-in-coronary-chronic-total-occlusion-100526651","NCT06137521","Risk Factors and Outcomes in Coronary Chronic Total Occlusion","Risk Factors and Outcomes in Patients With Stable Coronary Artery Disease and Coronary Chronic Total Occlusion","Inclusion Criteria:\n\n* Age ≥18 years; Patients with angina or silent ischemia and documented ischemia; Patients with CTO ≥ 3months\n\nExclusion Criteria:\n\n* eGFR\\\u003C15mL\u002F(min·1.73m2); Chronic heart failure with NYHA grade ≥3; Had a history of coronary artery bypass grafting; Had received a percutaneous coronary intervention within the prior 3 months; Malignant tumor or immune system disorders; Pulmonary heart disease",{"count":280,"type":22},3000,"OBSERVATIONAL","This study aims to assess the risk factors and evaluate the long-term outcomes of patients with coronary chronic total occlusion (CTO) treated with percutaneous coronary intervention or medical treatment.",[284,186],"Chronic Total Occlusion",{"date":220,"type":34},{"date":287,"type":34},"2010-01-01",{"date":289,"type":22},"2027-03-01",{"name":40,"class":41},{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":298,"minAge":76,"maxAge":77,"enrollmentInfo":299,"targetDuration":4,"studyType":23,"phases":301,"briefSummary":303,"conditions":304,"keywords":306,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":312,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":153},"100460596","phase-3-adjuvant-concurrent-chemoradiotherapy-versus-radiotherapy-in-early-stage-cervical-cancer-patients-100460596","NCT05277688","Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients","Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients With Selected Intermediate-risk Factors: a Randomized Controlled Phase III Trials (ACCEPT Trial)","Inclusion Criteria:\n\n* • 18 Years to 80 Years\n\n  * Histologically proven cervical cancer, FIGO stage Ia2-IIb,and no previous chemotherapy and radiotherapy\n  * Accepted radical hysterectomy 3-4 weeks before\n  * Karnofsky score \\>70\n  * Postoperative pathology with one of the three risk factors criterials: (1) lympho-vascular space invasion(LVSI+) and deep 1\u002F3 stromal invasion; (2 ) LVSI(+) and middle 1\u002F3 stromal invasion, and tumor size≥4cm (3)Non-squamous cell carcinoma;\n  * Examination results showed no radiation or chemotherapy contraindication\n  * Willing to accept treatment\n  * Ability to comply with trial requirements\n\nExclusion Criteria:\n\n* • Postoperative residual\n\n  * Postoperative recurrence or metastasis\n  * Pelvic lymph node metastasis\n  * parametrial invasion\n  * positive surgical margin\n  * Without lymph node dissection\n  * Postoperative pathology showed aortic lymph node metastasis\n  * Examination results showed radiotherapy contraindications\n  * No indications for radiotherapy","FEMALE",{"count":300,"type":22},340,[302],"PHASE3","To evaluate if adjuvant concurrent chemoradiotherapy is associated with a recurrence-free survival benefit in comparison with radiotherapy alone in selected intermediate risk cervical cancer after radical surgery.",[305],"Cervical Cancer",[307,308,309,310,311],"cervical cancer","early stage","chemoradiotherapy","radiotherapy","survival",{"date":220,"type":34},{"date":314,"type":34},"2022-03-15",{"date":316,"type":22},"2027-12-30",{"name":40,"class":41},{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":325,"targetDuration":327,"studyType":281,"phases":4,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":339,"locationsCount":68},"100428414","the-chinese-registry-of-prognostic-study-of-iga-nephropathy-crpiga-100428414","NCT04858724","The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)","Construction of a Multi-center Database for Primary IgA Nephropathy","Inclusion Criteria:\n\n1. No age limit, no gender limit;\n2. Kidney biopsy confirmed primary IgA nephropathy;\n3. Sign the informed consent form voluntarily\n\nExclusion Criteria:\n\n1. IgA nephropathy is secondary to systemic diseases such as systemic lupus erythematosus and allergic purpura;\n2. IgAN is clinically diagnosed but not confirmed by pathology;\n3. The patient refuses to participate;\n4. Patients judged by other investigators to be unsuitable for inclusion in the study.",{"count":326,"type":22},2000,"12 Months","1. Establish an IgAN cohort collaboration group and expert committee to carry out registration research.\n2. Construct IgAN structured data set standards, formulate structured data collection templates of diagnosis and treatment , and establish multi-center data integration systems on this basis.\n3. Establish a standardized IgAN database for combined Hospital Information System and the big data platform of the Medical Federation.\n4. Develop IgAN database managements and open standards for data sharing, and carry out high-quality clinical or basic research.",[330],"IgA Nephropathy",[332,333,334],"IgAN","database","multicenter",{"date":220,"type":34},{"date":337,"type":34},"2020-12-01",{"date":316,"type":22},{"name":40,"class":41},{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":77,"enrollmentInfo":347,"targetDuration":4,"studyType":23,"phases":349,"briefSummary":350,"conditions":351,"keywords":353,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":364,"locationsCount":68},"100561960","lymphocyte-sparing-thoracic-radiotherapy-for-esophageal-squamous-cell-carcinoma-100561960","NCT06596954","Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma","Lymphocyte-sparing Thoracic Radiotherapy vs Conventional Radiotherapy for Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Therapy: an Open Label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients are able to understand and are willing to participate in the trial, and a signed consent form can be obtained;\n2. Pathologically confirmed esophageal squamous cell carcinoma;\n3. locally advanced ESCC (cT3-4 or N+);\n4. the age of patients should be more than 18 years, and less than 80 years;\n5. aged between 18 and 80 years;\n6. KPS score of patients should be more than 80\n\nExclusion Criteria:\n\n1. diagnosis of metastatic esophageal cancer;\n2. Patient refuses to receive systemic drug treatment;\n3. clinical diagnosis of pleural metastasis or malignant pleural effusion;\n4. Pregnant or breastfeeding women;\n5. Severe non-cancerous medical comorbidities that affect the implementation of radiotherapy.",{"count":348,"type":22},212,[25],"Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignant tumors. Although neoadjuvant chemoradiotherapy combined with surgery has significantly improved the survival rate of patients with locally advanced esophageal cancer, approximately half of the patients will experience local regional recurrence or distant metastasis. Lymphocytes are crucial immune cells in the human body, playing a key role in combating infections and tumor development. In recent years, an increasing body of research has indicated that lymphocyte depletion is a significant factor associated with poor prognosis in various solid tumors, including esophageal cancer. The lymphocyte depletion caused by radiotherapy has garnered considerable attention from oncologists. However, there is still a lack of prospective clinical research data on lymphocyte protection in thoracic tumors. Therefore, this study aims to provide high-level evidence from evidence-based medicine regarding the correlation between lymphocyte depletion and prognosis in esophageal cancer patients, offering more effective strategies and methods to improve the outcomes of neoadjuvant chemoradiotherapy for esophageal cancer.",[352],"Esophageal Squamous Cell Cancer",[354,355,356,357],"esophageal cancer","neoadjuvant treatment","lymphocyte-sparing radiotherapy","prognosis","2026-08-10",{"date":360,"type":34},"2026-08-11",{"date":362,"type":34},"2024-06-30",{"date":316,"type":22},{"name":40,"class":41},{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":77,"enrollmentInfo":372,"targetDuration":4,"studyType":23,"phases":374,"briefSummary":375,"conditions":376,"keywords":378,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":68},"100481733","phase-ii-trial-of-consolidative-thoracic-radiotherapy-for-es-sclc-after-standard-care-of-chemo-immunotherapy-100481733","NCT05552846","Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy","Consolidative Thoracic Radiotherapy for Extensive-stage Small-cell Lung Cancer Treated With Chemo-immunotherapy Followed by PD-1\u002FPD-L1 Maintenance Therapy：an Open Label, Single Arm Prospective Trial","Inclusion Criteria:\n\n1. Age between18 years and 80 years at time of study entry\n2. ECOG performance status of 0 or 1\n3. Body weight \\>30 kg\n4. Adequate bone marrow, liver and kidney function\n5. Life expectancy of at least 3 months\n6. At least one measurable (RECIST 1.1), thoracic lesion that can be irradiated with 45 Gy\u002F15 fractions\n7. Histologic or cytologic confirmation of small cell lung cancer\n8. Stage III-IV disease (TNM v8)\n9. Adequate pulmonary function with FEV1 \\>1 L or \\>30 % of predicted value and DLCO \\>30 % of predicted value\n10. Patients with brain metastases are eligible provided they are asymptomatic or treated and stable on steroids and\u002For anticonvulsants prior to the start of treatment -\n\nExclusion Criteria:\n\n1. Previous chemo-, immuno- or radiotherapy for SCLC\n2. Major surgical procedure last 28 days\n3. History of allogenic organ transplantation, autoimmune disease, immunodeficiency, hepatitis or HIV\n4. Uncontrolled intercurrent illness\n5. Other active malignancy\n6. Leptomeningeal carcinomatosis\n7. Immunosuppressive medication\n8. Pregnant or breastfeeding women",{"count":373,"type":22},104,[25],"This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of thoracic radiotherapy for extensive-stage small-cell lung cancer treated with PD-1\u002FPD-L1 plus etoposide platinum followed by PD-1\u002FPD-L1 maintenance therapy",[377],"Small-cell Lung Cancer",[379,380,381],"thoradic radiotherapy","immune checkpoint inhibitors","chemo-immunotherapy",{"date":383,"type":34},"2026-08-12",{"date":385,"type":34},"2021-01-30",{"date":387,"type":22},"2027-09-30",{"name":40,"class":41},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":298,"minAge":76,"maxAge":77,"enrollmentInfo":396,"targetDuration":4,"studyType":23,"phases":398,"briefSummary":399,"conditions":400,"keywords":402,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":409,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":68},"100402208","evaluating-omitting-of-internal-mammary-irradiation-among-early-stage-intermediate-risk-n1-breast-cancer-100402208","NCT04517266","Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer","Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer Patients According to Clinical-genomic Model: an Open Label, Non-inferior Randomized Controlled Trial","Inclusion Criteria:\n\n* • Histologically confirmed invasive breast cancer\n\n  * Underwent radical surgery with either mastectomy or breast conserving surgery and axillary lymph node dissection (ALND)\n  * The number of positive lymph node should be 1-3 (N1).\n  * Clinical high risk breast cancer (≥2 clinical risk factors)\n  * Aged 18-80 years old\n  * ECOG performance status ≤2 (Karnofsky ≥70%) Anticipative overall survival \\>5 years Pathologically surgical margin \\>2mm ER (estrogen-receptor), PR (progesterone-receptor), HER2 (human epidermal growth factor receptor 2) and Ki67 testing can be performed on the primary breast tumor Women of child-bearing potential must agree to use adequate contraception for up to 1 month before study treatment and the duration of study participation Ability to understand and willingness to participate the research and sign the consent form\n\nExclusion Criteria:\n\n* • Axillary dissection of less than 10 lymph nodes\n\n  * Pathologically positive ipsilateral supraclavicular lymph node\n  * Pathologically or radiologically confirmed involvement of ipsilateral internal mammary lymph nodes\n  * Pregnant or lactating women\n  * Treated with breast reconstruction surgery\n  * Severe non-neoplastic medical comorbidities\n  * History of non-breast malignancy within 5 years with the exception of lobular carcinoma in situ, basal cell carcinoma of the skin, carcinoma in situ of skin and carcinoma in situ of the cervix\n  * simultaneous contralateral breast cancer\n  * Previous radiotherapy to the neck, chest and\u002For ipsilateral axillary region\n  * Active collagen vascular disease\n  * Definitive pathological or radiologic evidence of distant metastatic disease\n  * Primary T4 tumor\n  * Interval between radical surgery (mastectomy or breast conserving surgery) and radiotherapy was more than 12 weeks or interval between last dose of adjuvant chemotherapy and radiotherapy was more than 8 weeks",{"count":397,"type":22},214,[25],"The effect of internal mammary irradiation (IMI) added to whole-breast or thoracic-wall irradiation plus supraclavicular (SVC) irradiation after surgery on survival among women with early-stage intermediate risk (N1) breast cancer remains debated. The present study aimed to identified patient could be omitted from internal mammary lymph node irradiation by using a clinical-genomic model.",[401],"Breast Cancer",[403,404,405,406,310,407,408],"breast cancer","N1","clinical-genomic model","genomic model","internal mammary irradiation","clinical model",{"date":360,"type":34},{"date":411,"type":34},"2021-03-01",{"date":413,"type":22},"2030-10-30",{"name":40,"class":41},{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":422,"enrollmentInfo":423,"targetDuration":4,"studyType":23,"phases":424,"briefSummary":425,"conditions":426,"keywords":428,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":4},"100650935","transcranial-temporal-interference-stimulation-ttis-for-chronic-insomnia-100650935","NCT07755852","Transcranial Temporal Interference Stimulation (tTIS) for Chronic Insomnia","An Exploratory Randomized Controlled Clinical Trial of Transcranial Temporal Interference Stimulation (tTIS) for the Treatment of Chronic Insomnia","Inclusion Criteria:\n\n1. Aged 18 to 65 years old, male or female.\n2. Eligibility required an ICD-11 diagnosis of chronic insomnia disorder, determined by investigator-administered clinical interviews (≥3 nights\u002Fweek for ≥3 months, despite adequate opportunity\u002Fconditions for sleep, with daytime distress or functional impairment).\n3. Insomnia Severity Index (ISI) total score ≥ 15 at screening or baseline assessment.\n4. Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) total scores both ≤ 9 at screening assessment.\n5. Has full civil capacity, is able to proficiently operate a smartphone and wearable sleep band, and can understand and cooperate with clinical scale assessments and neurophysiological examinations.\n6. Voluntarily participates, can ensure on-time hospital visits for 10 transcranial temporal interference stimulation (tTIS) sessions over 2 consecutive weeks, and can cooperate with the 1-month longitudinal follow-up.\n7. Fully understands the study purpose, intervention procedures, and potential risks, and voluntarily signs the written informed consent form.\n\nExclusion Criteria:\n\n1. Psychiatric conditions: (1) schizophrenia spectrum disorder or bipolar disorder, determined based on participant self-report of prior clinician diagnosis and treatment history and, when feasible, review of available medical records; (2) moderate-to-severe depressive or anxiety symptoms (PHQ-9 ≥ 10 or GAD-7 ≥ 10; either threshold met); (3) current suicidal ideation\u002Fbehavior or elevated suicide risk as assessed by the investigator.\n2. Secondary sleep disorders: Severe obstructive sleep apnea (OSA; AHI ≥ 30), restless legs syndrome (RLS), narcolepsy, or severe circadian rhythm disorders.\n3. Epilepsy risk: History of seizures\u002Fconvulsions or a clear family history of epilepsy.\n4. Intracranial metal and implanted electronic devices: Intracranial metal implants (e.g., aneurysm clips, metal stents, repair patches; fixed dental fillings excluded) or implanted electronic devices (e.g., cardiac pacemakers, deep brain stimulators \\[DBS\\], vagus nerve stimulators \\[VNS\\]).\n5. Medical history (neurologic): Recent craniotomy, severe traumatic brain injury, or organic brain lesions (e.g., brain tumors).\n6. Special populations: Pregnant, lactating, or planning pregnancy during the study period.\n7. Skin and physical restrictions: Skin damage, infection, or severe rash at the scalp stimulation site (especially over the left DLPFC and the return electrode site), or severe allergy to conductive gel\u002Felectrodes.\n8. Somatic comorbidities\u002Fsubstance use: Severe cardiac, pulmonary, hepatic, or renal dysfunction, or other conditions deemed by the investigator to potentially affect participant safety or study assessments (e.g., severe alcohol or drug abuse).","65 Years",{"count":142,"type":22},[25],"The purpose of this exploratory randomized controlled clinical trial is to evaluate the efficacy and safety of transcranial temporal interference stimulation (tTIS) in the treatment of chronic insomnia. The study aims to investigate whether non-invasive tTIS intervention can effectively modulate specific neural activities to improve sleep quality and alleviate related clinical symptoms in patients suffering from chronic insomnia.\n\nParticipants enrolled in this study will be randomly assigned to receive either active tTIS treatment or sham stimulation. Researchers will collect clinical assessments and sleep monitoring data before, during, and after the intervention to compare the outcomes between the different groups and determine the therapeutic potential of tTIS for insomnia management.",[427],"Chronic Insomnia",[429,427,430],"Non-invasive Brain Stimulation","Dorsolateral Prefrontal Cortex","2026-08-04",{"date":358,"type":34},{"date":434,"type":22},"2026-08-30",{"date":436,"type":22},"2027-04-30",{"name":40,"class":41},{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":23,"phases":447,"briefSummary":448,"conditions":449,"keywords":453,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":68},"100650128","phase-2-safety-and-efficacy-of-multimodal-thermal-therapy-mtt-combined-with-kras-g12v-mrna-vaccine-s-1-and-sintilimab-in-patients-with-metastatic-pancreatic-cancer-100650128","NCT07745790","Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer","A Study of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab for Safety and Efficacy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Disease Progression After or Are Intolerant to Standard First-Line Therapy","Inclusion Criteria:\n\n* Aged ≥ 18 years old with no restriction on gender.\n* Patients with advanced pancreatic cancer or postoperative recurrent pancreatic cancer confirmed by histopathological or cytological examination.\n* Tumor tissues are confirmed to carry KRAS G12V mutation via sequencing and bioinformatics analysis (valid test reports obtained within the previous 12 months and recognized by the investigator are acceptable). In the dose expansion phase, patients must harbor at least one HLA allele capable of effectively presenting the corresponding antigen, including HLA-A11:01, HLA-A03:01, HLA-A30:01, HLA-A68:01, HLA-C01:02, HLA-C03:03, and HLA-C03:04.\n* Disease resistance or intolerance to prior AG-based chemotherapy regimens.\n* Presence of liver metastasis or lung metastasis.\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.\n* Child-Pugh score ≤ 7 points.\n* Expected overall survival of at least 3 months.\n\nExclusion Criteria:\n\n* Presence of diffuse hepatic or pulmonary metastases.\n* Prior local treatment including radiofrequency ablation, microwave ablation, radiotherapy or other local therapies for metastatic lesions.\n* Current participation in other interventional clinical studies and receiving investigational treatment.\n* Diagnosis of any other malignant disease within 5 years prior to the first study drug administration (excluding radically treated basal cell carcinoma, squamous cell carcinoma of the skin, and\u002For radically resected in situ carcinoma).\n* Prior history of solid organ or hematopoietic stem cell transplantation.\n* Any disease requiring systemic treatment with corticosteroids (prednisone or equivalent daily dose \\> 10 mg) or other immunosuppressive agents within 14 days prior to enrollment.\n* Previous or current diagnosis of brain metastases with incompletely controlled symptoms (i.e., persistent or aggravated symptoms, or requirement for adjusted symptomatic treatment to maintain symptom relief).\n* Presence of uncontrolled active infection.\n* Renal dysfunction defined as serum creatinine \\> 176.8 μmol\u002FL or creatinine clearance \\\u003C 30 mL\u002Fmin.\n* Uncorrectable coagulation abnormalities, including platelet count \\\u003C 50×10⁹\u002FL, prothrombin time \\> 18 seconds, or prothrombin activity \\\u003C 40%, which cannot be corrected.\n* History of esophagogastric variceal rupture without effective treatment via endoscopy, interventional therapy or surgery.\n* Patients with psychiatric disorders in the acute episode stage.\n* Women of childbearing potential who are pregnant, breastfeeding, or planning to become pregnant during the study treatment period or within 3 months after the end of study treatment.\n* Prior systemic pharmacotherapy, radiotherapy or local hepatic treatment with an interval of \\\u003C 1 month from the last systemic or local hepatic treatment to the first study drug administration.",{"count":446,"type":22},20,[124],"This is a single-arm, single-center, exploratory clinical study. A total of 20 participants with metastatic pancreatic ductal adenocarcinoma (with liver or lung metastasis) who have experienced disease progression after or are intolerant to standard first-line chemotherapy (based on the AG regimen \\[Albumin-bound Paclitaxel plus Gemcitabine\\]) will be enrolled.The study aims to evaluate the safety, efficacy, and underlying immunological mechanisms of Multimodal Thermal Therapy (MTT) combined with a KRAS G12V mRNA vaccine, S-1, and Sintilimab.",[450,451,452],"Pancreatic Ductal Adenocarcinoma","Liver Neoplasms","Lung Neoplasms",[454,455,456],"Multimodal Thermal Therapy","mRNA","Metastatic Pancreatic Cancer","2026-07-30",{"date":431,"type":34},{"date":460,"type":22},"2026-07-13",{"date":462,"type":22},"2029-07-31",{"name":40,"class":41},{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":23,"phases":472,"briefSummary":474,"conditions":475,"keywords":476,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":68},"100645281","early-phase-1-an-exploratory-study-of-personalized-cancer-vaccine-in-adjuvant-therapy-of-solid-tumors-100645281","NCT07680582","An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors","An Exploratory Study of Personalized Cancer Vaccine (ABO2109) in Adjuvant Therapy of Solid Tumors","Key Inclusion Criteria:\n\n1. ≥18 years of age at time of informed consent\n2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1\n3. Life expectancy of ≥6 months\n4. Patient diagnosed with solid tumors and is receiving perioperative and\u002For adjuvant anti-cancer therapy, or patients with advanced solid tumors\n5. No evidence of disease progression per investigator within 28 days before the first dose of study intervention\n6. Sufficient organ function\n7. Female patients must meet both of the criteria: a) Surgically sterile, or postmenopausal for ≥2 years, or women of childbearing potential with a negative pregnancy test and willing to use effective contraception during the study and for at least 90 days after the last study dose. Use of progesterone-containing contraceptives is not permitted. b) Agree not to breastfeed during the study and for at least 90 days after the last study dose.Male patients must meet the following criteria:If not surgically sterile and potentially engaging in sexual activity that could lead to pregnancy, agree to use effective contraception during the study and for at least 90 days after the last study dose.\n\nKey Exclusion Criteria:\n\n1. For perioperative or adjuvant therapy setting, participants have received systemic anti-tumor treatment previously\n2. Any other prior malignancy active within the previous 5 years, except for skin basal cell cancer that has been cured, or superficial bladder cancer, carcinoma in situ of the breast, carcinoma in situ of the cervix, thyroid cancer\n3. Presence of active or prior history of interstitial lung disease, tuberculosis, or any other condition known to compromise pulmonary function.\n4. Presence of active infections\n5. History of severe cardiovascular or cerebrovascular diseases occurring within 6-month prior to study treatment\n6. Known hypersensitivity to the active ingredients or excipients of ABO2109 or toripalimab.",{"count":52,"type":22},[473],"EARLY_PHASE1","The purpose of this study is to evaluate the safety and tolerability of ABO2109 in combination with toripalimab, and to evaluate the immunogenicity, pharmacokinetics, pharmacodynamics, as well as biomarker characteristics of the investigational cancer vaccine. In addition, the antitumor activity of ABO2109 will be assessed during both dose exploration and expansion stages, the accumulative data will support the clinical development of ABO2109.",[83],[40],{"date":478,"type":34},"2026-08-03",{"date":480,"type":34},"2026-06-09",{"date":482,"type":22},"2031-02-09",{"name":40,"class":41},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":23,"phases":493,"briefSummary":494,"conditions":495,"keywords":498,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":506,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":68},"100643965","electrical-impedance-tomography-guided-identification-of-the-optimal-lateral-position-in-postoperative-ards-100643965","NCT07669558","Electrical Impedance Tomography-Guided Identification of the Optimal Lateral Position in Postoperative ARDS","Effect of Left Lateral, Right Lateral, and Supine Positioning on Ventilation-Perfusion Matching Assessed by Electrical Impedance Tomography in Adult Postoperative Abdominal Surgery Patients With ARDS: A Prospective Randomized Crossover Physiological Study","Inclusion Criteria:\n\n* Age ≥18 years\n* Postoperative abdominal surgery patients admitted to the ICU with ARDS (Berlin definition)\n* Considered able to tolerate protocolized position changes by the treating team\n* EIT belt placement and protocol procedures feasible\n* Informed consent obtained from the patient or legally authorized representative\n\nExclusion Criteria:\n\n* Contraindication to lateral positioning (e.g., unstable spine, uncontrolled bleeding, open abdomen, high-risk surgical wound condition)\n* Severe hemodynamic instability or other conditions making participation unsafe\n* High risk of airway\u002Fvascular line\u002Fdrain dislodgement not manageable\n* Pregnancy\n* Refusal of informed consent\n* Any other condition deemed inappropriate by investigators",{"count":492,"type":22},22,[25],"This prospective, randomized crossover physiological study evaluates the effects of lateral positioning (left lateral position and right lateral position) versus the supine position on ventilation-perfusion (V\u002FQ) matching in adult postoperative abdominal surgery participants with acute respiratory distress syndrome (ARDS). Bedside electrical impedance tomography (EIT) will be used to quantify regional ventilation and perfusion (perfusion derived from an intravenous tracer bolus administered during a brief breath-hold) and to calculate global \"normal V\u002FQ\" (normal V\u002FQ, %). Oxygenation, respiratory mechanics (when applicable), and hemodynamics will be recorded concurrently. Feasibility and safety of the positioning protocol will also be assessed.",[496,497],"Acute Respiratory Distress Syndrome (ARDS)","Postoperative",[499,500,501,502,503,504,505],"acute respiratory distress syndrome (ARDS)","electrical impedance tomography (EIT","Lateral position","ventilation-perfusion","postoperative abdominal surgery","crossover study","supine position",{"date":478,"type":34},{"date":508,"type":34},"2026-06-28",{"date":510,"type":22},"2026-10-31",{"name":40,"class":41},{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":23,"phases":521,"briefSummary":522,"conditions":523,"keywords":525,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":68},"100635132","phase-2-study-of-sax-in-the-treatment-of-newly-diagnosed-aml-100635132","NCT07548710","Study of SA+X in the Treatment of Newly Diagnosed AML","Clinical Study of Sonrotoclax Combined With Azacitidine Plus Individualized Targeted Drugs in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia","Inclusion Criteria:\n\n* Newly diagnosed AML confirmed by bone marrow morphology and immunophenotyping (5th edition WHO diagnostic criteria)\n* Subjects with APL excluded according to fusion gene and chromosome results\n* ECOG performance status 0-3\n* Age ≥ 18 years\n* White blood cell count must be \\\u003C 25 × 10⁹\u002FL at the start of study treatment (can be reduced by leukapheresis and\u002For hydroxyurea)\n* Subjects must have adequate organ function, defined as follows: Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN), unless elevated due to leukemic organ involvement; serum total bilirubin \\\u003C 3 × ULN; higher levels are acceptable if attributable to ineffective erythropoiesis, leukemic organ involvement, or Gilbert syndrome; serum creatinine \\\u003C 3 × ULN, or estimated creatinine clearance ≥ 30 mL\u002Fmin by Cockcroft-Gault formula\n* Written informed consent obtained from the subject or legal representative\n\nExclusion Criteria:\n\n* FAB classification as M3, or molecularly confirmed APL\n* Refractory \u002F relapsed subjects\n* Subjects with a history of myeloproliferative neoplasms (MPN);\n* Subjects with a history of chronic myeloid leukemia (CML);\n* Subjects with mixed phenotype acute leukemia (MPAL);\n* Documented central nervous system leukemia;\n* Hypersensitivity or allergy to any of the study drugs;\n* Physical conditions or organ system dysfunction that impairs the ability to swallow capsules or tablets, or significantly affects gastrointestinal function and\u002For absorption (including malabsorption syndrome, small bowel resection, or uncontrolled inflammatory bowel disease);\n* Cardiac conditions meeting any of the following:a) Long QT syndrome or QTc interval \\> 480 ms;b) Second- or third-degree atrioventricular block; severe, uncontrolled arrhythmia requiring medical treatment;c) History of myocardial infarction, unstable angina, severe unstable ventricular arrhythmia, or any other treatable arrhythmia, clinically significant pericardial disease within 6 months prior to enrollment; or electrocardiographic evidence of acute ischemia or active conduction system abnormalities;\n* Current concurrent malignancy other than adequately controlled non-melanoma skin basal cell carcinoma, in situ breast\u002Fcervical carcinoma, or other malignancies adequately controlled without treatment for more than 6 months;\n* Significantly abnormal liver or renal function (serum bilirubin, AST, ALT, or serum creatinine \\> 3 × upper limit of normal; excluding those deemed by the investigator to be related to AML);\n* Subjects who have received previous anti-AML therapies other than hydroxyurea for cytoreduction, including but not limited to BCL-2, FLT3, IDH1 inhibitors, or other investigational agents;\n* Coagulopathy unrelated to AML;\n* HIV infection, syphilis infection, HCV infection, or active HBV infection (HBsAg positive; or HBsAg negative \u002F HBcAb positive with HBV DNA \\> 1.0 × ULN); Patients with previously documented such infections who have achieved undetectable viral load or sustained viral load reduction after treatment may be enrolled at the investigator's discretion;\n* Other uncontrolled active infection (as judged by the investigator);\n* Pregnant or breastfeeding women;\n* Unable to understand or comply with the study protocol;\n* Participation in other relevant clinical studies within 30 days (excluding diagnostic studies);\n* Subjects deemed inappropriate for study participation by the investigator.",{"count":520,"type":22},205,[124],"This is a phase II, open-label, multi-center study evaluating the efficacy and safety of sonrotoclax (SA) in combination with azacitidine (AZA) plus individualized targeted or chemotherapeutic agents in adult participants with newly diagnosed acute myeloid leukemia (AML). Eligible participants will be stratified into different treatment arms based on genetic background (FLT3\u002FIDH1 mutation status) and fitness for intensive chemotherapy. All participants will receive sonrotoclax with dose escalation from 20 mg\u002Fday to 320 mg\u002Fday, followed by maintenance dosing, which may be temporarily held by the investigator from Day 14 to Day 28 of each 28-day cycle based on the participant's condition, combined with azacitidine 75 mg\u002Fm²\u002Fday intravenously on Days 1-7. For participants fit for intensive chemotherapy, additional anthracycline (daunorubicin 60 mg\u002Fm²\u002Fday or idarubicin 10 mg\u002Fm²\u002Fday on Days 1-3) will be administered. For participants with FLT3 mutations, gilteritinib 80 mg once daily on Days 1-14 will be added; for those with IDH1 mutations, ivosidenib 500 mg once daily on Days 1-28 will be added.",[524],"Acute Myeloid Leukemia",[526,527,528],"Newly Diagnosed Adult Acute Myeloid Leukemia","Sonrotoclax","Azacitidine","2026-07-29",{"date":457,"type":34},{"date":532,"type":34},"2026-05-01",{"date":534,"type":22},"2028-12-21",{"name":40,"class":41},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":18,"minAge":542,"maxAge":98,"enrollmentInfo":543,"targetDuration":4,"studyType":23,"phases":545,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":153},"100592843","phase-1-regend001-autologous-basal-layer-stem-cell-transplantation-for-interstitial-lung-disease-ild-a-translational-application-study-100592843","NCT06998706","REGEND001 Autologous Basal Layer Stem Cell Transplantation for Interstitial Lung Disease (ILD): A Translational Application Study","Inclusion Criteria:\n\n1. Age 40-75 years.\n2. Confirmed diagnosis of ILD (e.g., IPF, connective tissue disease-associated ILD).\n3. DLCO ≥30% and \\\u003C80% predicted.\n\nExclusion Criteria:\n\n1. Pregnancy, lactation, or plans for pregnancy within 1 year.\n2. Active malignancy or history of malignancy.\n3. Positive serology for HIV, HBV, HCV, or syphilis.","40 Years",{"count":544,"type":22},10,[102],"This clinical trial evaluates the safety and efficacy of REGEND001, an autologous bronchial basal layer stem cell therapy, in patients with interstitial lung disease (ILD). The treatment involves harvesting the patient's own stem cells (expressing KRT5\u002FP63 markers), expanding them ex vivo, and administering them via bronchoscopic infusion to regenerate damaged lung tissue.",[548],"Interstitial Lung Disease (ILD)",{"date":550,"type":34},"2026-07-28",{"date":552,"type":34},"2025-06-19",{"date":554,"type":22},"2029-06-30",{"name":40,"class":41},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":560,"acronym":4,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":18,"minAge":562,"maxAge":77,"enrollmentInfo":563,"targetDuration":4,"studyType":23,"phases":564,"briefSummary":565,"conditions":566,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":568,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":153},"100591960","phase-1-regend001-autologous-basal-layer-stem-cell-transplantation-for-bronchiectasis-a-translational-application-study-100591960","NCT06987214","REGEND001 Autologous Basal Layer Stem Cell Transplantation for Bronchiectasis: A Translational Application Study","Inclusion Criteria:\n\n1. Age 25-80 years.\n2. Confirmed diagnosis of bronchiectasis.\n3. FEV1 ≥35% predicted; DLCO ≥30% and \\\u003C80% predicted.\n\nExclusion Criteria:\n\n1. Pregnancy, lactation, or plans for pregnancy within 1 year.\n2. Active malignancy or history of malignancy.\n3. Positive serology for HIV, HBV, HCV, or syphilis.","25 Years",{"count":544,"type":22},[102],"This clinical trial aims to evaluate the safety and efficacy of REGEND001, an autologous basal layer stem cell transplantation therapy, in patients with chronic structural lung disease (bronchiectasis). The treatment involves harvesting bronchial basal layer stem cells from the patient, expanding them ex vivo, and reintroducing them via bronchoscopic infusion to repair damaged lung tissue.",[567],"Bronchiectasis Adult",{"date":550,"type":34},{"date":570,"type":34},"2025-06-18",{"date":572,"type":22},"2029-05-30",{"name":40,"class":41},{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":23,"phases":582,"briefSummary":583,"conditions":584,"keywords":587,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":593,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":68},"100556015","phase-2-systemic-application-of-cadonilimab-lm-302-and-s-1-combined-with-intraperitoneal-infusion-of-paclitaxel-for-the-treatment-of-claudin-182-positive-gastric-cancer-with-peritoneal-metastasis-100556015","NCT06519591","Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis","Inclusion Criteria:\n\n1. Histologically confirmed gastric adenocarcinoma with her 2 (-), and without the history of resection of primary or metastatic lesion;\n2. Peritoneal metastases from gastric cancer requiring definitive diagnosis by laparoscopy, and without gastric outflow tract obstruction and intestinal obstruction; Written (signed) informed consent;\n3. Claudin 18.2 positive (≥ 25%, and the proportion of positive cells greater than 50% of the cases accounted for not less than 70%);\n4. Age ≥ 18 years at registration;\n5. Eastern Cooperative Oncology Group (ECOG) score ≤ 1;\n6. Expected life expectancy \\> 3 months;\n7. Adequate bone marrow, liver, and renal functions.\n\nExclusion Criteria:\n\n1. Confirmed of evidence of distant metastasis other than peritoneal metastasis (e.g.liver metastasis, lung metastasis, para-aortic lymph node metastasis, etc.);\n2. During pregnancy, within 28 days of post parturition, or during lactation;\n3. Previously received immunotherapy such as PD-1\u002FPD-L1 and CTLA-4 or targeted therapy such as Claudin 18.2.\n4. Synchronous or metachronous (within 5 years) malignancies.\n5. Severe mental disease, uncontrolled epilepsy, or central nervous system disease;\n6. Clinically severe (i.e. active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or arrhythmia requiring drug intervention, or a history of myocardial infarction in the last 12 months;\n7. Upper gastrointestinal obstruction or abnormal physiological function or malabsorption syndrome may affect S-1 absorbers;\n8. Known peripheral neuropathy (\\> NCI-CTC AE 1). However, patients with only disappearance of deep tendon reflex (DTR) need not be excluded;\n9. Patients on steroid or immunosuppressant treatment after organ transplant;\n10. Patients with severe uncontrolled recurrent infections or other severe uncontrolled concomitant disease;\n11. Moderate or severe renal damage \\[creatinine clearance ≤ 50 ml\u002Fmin\\], or serum creatinine \\> upper limit of normal (ULN), 115 μmol\u002FL;\n12. Known dihydropyrimidine dehydrogenase (DPD) deficiency;\n13. Anaphylaxis to paclitaxel or any research drug ingredient.\n14. Active autoimmune disease or history of refractory autoimmune disease;\n15. Subjects with hypothyroidism requiring only hormone replacement therapy and skin diseases without systemic treatment (such as vitiligo, psoriasis or alopecia) can be selected;\n16. HIV antibody positive, active hepatitis B or C (hepatitis B: HBsAg positive and HBV DNA ≥10 copies\u002Fml; hepatitis C: HCV antibody and HCV-RNA positive, requiring antiviral treatment at the same time);\n17. Steroid or other systemic immunosuppressive therapy was used 14 days before admission, excluding local or physiological doses of systemic glucocorticoids (eg. no more than 10mg\u002Fday of prednisone or other glucocorticoids of equivalent dose) by nasal spray, inhalation or other routes, or hormones used to prevent allergy of contrast agents;\n18. Uncontrolled arrhythmia and myocardial infarction within 12 months before admission or active tuberculosis.",{"count":581,"type":22},40,[124],"In this phase 2 study, we combined Cadonilimab, LM-302, and S-1 combined with intraperitoneal infusion of paclitaxel as regimen to treat gastric cancer patients with peritoneal metastasis.",[585,586],"Gastric Cancer Stage IV","Peritoneal Metastases",[588,589,590,591,592],"Gastric cancer","Peritoneal metastasis","Cadonilimab","Claudin 18.2","Paclitaxel",{"date":529,"type":34},{"date":595,"type":34},"2025-02-25",{"date":597,"type":22},"2027-01",{"name":40,"class":41},""]